PL2010501T3 - Związki oparte na imidazolu, zawierające je kompozycje i sposoby ich stosowania - Google Patents

Związki oparte na imidazolu, zawierające je kompozycje i sposoby ich stosowania

Info

Publication number
PL2010501T3
PL2010501T3 PL07751414T PL07751414T PL2010501T3 PL 2010501 T3 PL2010501 T3 PL 2010501T3 PL 07751414 T PL07751414 T PL 07751414T PL 07751414 T PL07751414 T PL 07751414T PL 2010501 T3 PL2010501 T3 PL 2010501T3
Authority
PL
Poland
Prior art keywords
imidazole
compositions
methods
based compounds
compounds
Prior art date
Application number
PL07751414T
Other languages
English (en)
Inventor
David J Augeri
Jeffrey Bagdanoff
Lakmal W Boteju
Kenneth G Carson
Theodore C Jessop
David S Kimball
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PL2010501T3 publication Critical patent/PL2010501T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07751414T 2006-02-24 2007-02-21 Związki oparte na imidazolu, zawierające je kompozycje i sposoby ich stosowania PL2010501T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77647306P 2006-02-24 2006-02-24
US81522106P 2006-06-20 2006-06-20
US11/698,253 US7649098B2 (en) 2006-02-24 2007-01-25 Imidazole-based compounds, compositions comprising them and methods of their use
EP07751414.9A EP2010501B1 (en) 2006-02-24 2007-02-21 Imidazole-based compounds, compositions comprising them and methods of their use
PCT/US2007/004648 WO2007100617A2 (en) 2006-02-24 2007-02-21 Imidazole-based compounds, compositions comprising them and methods of their use

Publications (1)

Publication Number Publication Date
PL2010501T3 true PL2010501T3 (pl) 2014-09-30

Family

ID=38320192

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07751414T PL2010501T3 (pl) 2006-02-24 2007-02-21 Związki oparte na imidazolu, zawierające je kompozycje i sposoby ich stosowania

Country Status (20)

Country Link
US (3) US7649098B2 (pl)
EP (2) EP2090334B1 (pl)
JP (1) JP5153655B2 (pl)
KR (1) KR20080096570A (pl)
AU (1) AU2007221265B2 (pl)
BR (1) BRPI0710076A2 (pl)
CA (1) CA2643021C (pl)
DK (1) DK2010501T3 (pl)
EA (1) EA015783B1 (pl)
EC (1) ECSP088692A (pl)
ES (1) ES2456673T3 (pl)
IL (1) IL193297A (pl)
MX (1) MX2008010772A (pl)
NO (1) NO20084024L (pl)
NZ (1) NZ570308A (pl)
PL (1) PL2010501T3 (pl)
PT (1) PT2010501E (pl)
SG (1) SG170024A1 (pl)
WO (1) WO2007100617A2 (pl)
ZA (1) ZA200806842B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102097458B (zh) 2004-06-04 2013-10-30 伊利诺伊大学评议会 用于制造并组装可印刷半导体元件的方法和设备
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) * 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
UY31013A1 (es) * 2007-04-12 2008-09-02 Lexicon Pharmaceuticals Inc Metodos para prepar compuestos basados en imidazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
CN102083454A (zh) * 2008-03-31 2011-06-01 纽约市哥伦比亚大学托管会 诊断、预防和治疗骨量疾病的方法
TW201004943A (en) * 2008-06-18 2010-02-01 Lexicon Pharmaceuticals Inc Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
KR20220084423A (ko) 2008-07-23 2022-06-21 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
CA2733671C (en) 2008-08-27 2018-01-02 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
AR074061A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
US20110098482A1 (en) * 2009-10-26 2011-04-28 Wenxue Wu Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
JP5645318B2 (ja) * 2010-02-18 2014-12-24 第一三共株式会社 イミダゾール誘導体
CN102884064B (zh) 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
WO2012002274A1 (ja) 2010-06-28 2012-01-05 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
JP5960138B2 (ja) * 2011-06-28 2016-08-02 第一三共株式会社 リン酸エステル誘導体
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions
TR201302590A2 (tr) * 2013-03-04 2014-09-22 S Gueniz Kuecuekguezel Diflunisalden hareketle yeni bileşiklerin sentezi.
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CN111032041A (zh) 2017-05-16 2020-04-17 健艾仕生物医药有限公司 治疗类风湿关节炎的组合物和方法
EP3443986A1 (en) * 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
WO2025027051A1 (en) * 2023-07-31 2025-02-06 Ab Science Sphingosine-1-phosphate lyase inhibitors for use in the treament of neurodegenerative diseases

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788548A (fr) * 1971-09-10 1973-03-08 Bayer Ag Nouveaux acides 2-imidazolyl-carbonyl-benzoiques, leurs esters et leur sels, leur procede de preparation et leur application comme regulateursde croissance des vegetaux
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
US4614662A (en) * 1985-08-26 1986-09-30 D. D. Williamson & Co., Inc. Fast cook-continuous process for production of ammonia caramel color
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993006118A1 (en) 1991-09-26 1993-04-01 Smithkline Beecham Plc Antibacterial, antimycoplasmal compounds related to mupirocin
GB9201391D0 (en) 1992-01-22 1992-03-11 Smithkline Beecham Plc Method of treatment
DE4205081A1 (de) 1992-02-20 1993-08-26 Bayer Ag 1-acyloxy-2-azolyl-ethane
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5519040A (en) * 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
SE9401965D0 (sv) * 1994-06-07 1994-06-07 Astra Ab New compounds
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
JPH10504542A (ja) * 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
CN1093535C (zh) * 1994-09-26 2002-10-30 盐野义制药株式会社 咪唑衍生物
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
AU2881797A (en) 1996-05-31 1998-01-05 University Of Wollongong, The Acetyl derivatives of thiazoles and analogues
US6207371B1 (en) 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6423527B1 (en) * 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
DK1188747T3 (da) * 1999-05-24 2006-01-23 Mitsubishi Pharma Corp Phenoxypropylaminforbindelser
AU5300000A (en) 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
DE10025672A1 (de) 2000-05-24 2001-11-29 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
DE10111936C1 (de) * 2001-03-13 2002-10-02 Wella Ag N-Heteroarylmethyl-m-phenylendiamin-Derivate enthaltende Haarfärbemittel sowie neue N-Heteroarylmethyl-m-phenylendiamin-Derivate
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
EP1392441B1 (en) 2001-06-05 2008-07-23 Elan Pharma International Limited System and method for milling materials
DE10130145A1 (de) * 2001-06-22 2003-01-02 Wella Ag Kationische Farbstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Färbemittel
ATE526319T1 (de) * 2001-08-10 2011-10-15 Nippon Chemiphar Co Aktivator für den peroxisome proliferator- responsiven rezeptor delta
AU2002323475B2 (en) * 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
US6692960B2 (en) * 2001-09-28 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of sphingosine-1-phosphate lyase expression
EP1553927B9 (en) 2002-09-11 2011-09-21 Elan Pharma International Limited Gel-stabilized nanoparticulate active agent compositions
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
MXPA06007054A (es) * 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
WO2005072412A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
JP4853284B2 (ja) * 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW200920355A (en) 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders

Also Published As

Publication number Publication date
NZ570308A (en) 2010-09-30
EA015783B1 (ru) 2011-12-30
US20130005775A1 (en) 2013-01-03
IL193297A0 (en) 2009-08-03
AU2007221265B2 (en) 2012-08-02
US20070208063A1 (en) 2007-09-06
WO2007100617A2 (en) 2007-09-07
EP2090334B1 (en) 2015-04-29
US8093267B2 (en) 2012-01-10
EP2010501A2 (en) 2009-01-07
IL193297A (en) 2013-03-24
US20100076030A1 (en) 2010-03-25
CA2643021A1 (en) 2007-09-07
EA200870292A1 (ru) 2009-02-27
US8404732B2 (en) 2013-03-26
CA2643021C (en) 2015-04-07
EP2090334A3 (en) 2009-09-23
MX2008010772A (es) 2008-09-01
ZA200806842B (en) 2009-12-30
BRPI0710076A2 (pt) 2011-08-02
NO20084024L (no) 2008-11-06
AU2007221265A1 (en) 2007-09-07
DK2010501T3 (da) 2014-06-30
ECSP088692A (es) 2008-11-27
JP2009527564A (ja) 2009-07-30
EP2090334A2 (en) 2009-08-19
EP2010501B1 (en) 2014-04-02
WO2007100617A3 (en) 2008-01-17
ES2456673T3 (es) 2014-04-23
KR20080096570A (ko) 2008-10-30
PT2010501E (pt) 2014-05-07
SG170024A1 (en) 2011-04-29
JP5153655B2 (ja) 2013-02-27
US7649098B2 (en) 2010-01-19

Similar Documents

Publication Publication Date Title
ZA200806842B (en) Imidazole-based compounds,compositions comprising them and methods of their use
ZA201001300B (en) Antigen-asjuvant compositions and methods
LT2963031T (lt) Tetrahidrokanabinolio provaistai, provaistus apimančios tetrahidrokanabinolio kompozicijos ir jų panaudojimo būdai
PL2137210T3 (pl) Nowy sposób i kompozycje
ZA200808431B (en) Fungicidal compositions and methods of using the same
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
GB0721291D0 (en) Methods and compositions
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
EP2340297A4 (en) COMPOSITION, ITS MANUFACTURING METHOD AND USE
GB0706077D0 (en) Methods, Compositions and uses thereof
GB0601143D0 (en) Uses, methods and compositions
IL211204A0 (en) Mucoadherents compositions and their use
IL205248A0 (en) Compositions and methods for making androstenediones
GB0717376D0 (en) Composition and manufacture thereof
GB0719526D0 (en) Compositions and methods
GB0819432D0 (en) Compound, composition and use
GB0715428D0 (en) Compositions and uses thereof
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB0723775D0 (en) Methods and compositions
GB0717683D0 (en) Compositions and methods